. Author manuscript; available in PMC: 2013 Dec 1.

Published in final edited form as: J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):e60–e63. doi: 10.1097/QAI.0b013e31827171d7

Table 1.

Drug Resistance score, HIV RNA, CD4+ cell count and markers of immune activation at baseline and changes after treatment interruption.

	Baseline	Change from Baseline
	Median (Q1, Q3)	Median (Q1, Q3)	p-value^*
PI Score (n=16)	2.5 (1.5, 4.0)	−1.0 (−3.5, 0)	0.008
NNRTI Score (n=16)	1.0 (1.0, 2.0)	0 (−1.0, 0)	0.02
NRTI Score (n=16)	4.0 (1.0, 5.5)	−1.0 (−2.5, 0)	0.002
HIV RNA (log₁₀ copies/ml) (n=16)	4.8 (4.3, 5.3)	0.2 (0.1, 0.8)	0.006
CD4 (cells/mm³) (n=15)	217 (87, 329)	−54 (−85, −6)	<0.001
*Cellular Activation Markers* (n=15):
% CD38+ CD8 cells	85 (74, 90)	4 (−2, 8)	0.15
% CD38+/HLA-DR+ CD8 cells	47 (37, 66)	4 (−4, 9)	0.35
% CD38+/HLA-DR+ CD4 cells	17 (13, 31)	3 (2, 8)	0.03
*Soluble Activation Markers* (n=16):
TNF-α (log₁₀ pg/ml)	2.8 (2.2, 2.9)	0.3 (−0.1, 0.7)	0.04
TNF-rII (log₁₀ pg/ml)	3.5 (3.3, 3.6)	0.03 (−0.01, 0.1)	0.08
IL-6 (log₁₀ pg/ml)	1.1 (0.8, 1.6)	0.4 (−0.03, 0.8)	0.04

Signed rank test (2-tailed).